Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2021-11-10 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'IRLAB THERAPEUTICS AB (PUBL) 2021 Interim report July – September'. It contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and key financial ratios for the group and parent company for the period ending September 30, 2021. It also includes management commentary (CEO's comment) and operational updates. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2021
2021-11-10 English
Nomination committee in IRLAB appointed ahead of annual general meeting 2022
Board/Management Information Classification · 99% confidence The document explicitly discusses the appointment of members to the nomination committee ahead of the 'annual general meeting 2022' (AGM 2022). It details the composition of the committee, which is directly related to corporate governance and preparations for the AGM. While it mentions the AGM, the core content is about the committee structure and governance, which aligns closely with Governance Information (CGR). However, since the context is specifically about the nomination committee whose proposals are presented at the AGM, and the document is an announcement regarding this preparatory step, it relates strongly to the governance structure leading up to the meeting. Given the options, 'Governance Information' (CGR) is the best fit for detailing the structure and rules of a committee related to board nominations and shareholder proposals, which is a key aspect of corporate governance. It is not a presentation (IP), a transcript (CT), or a formal voting result (DVA), but rather an announcement about the governance body responsible for nominations.
2021-11-05 English
Valberedningen utsedd inför IRLABs årsstämma 2022
Board/Management Information Classification · 99% confidence The document is a press release titled "Valberedningen utsedd inför IRLABs årsstämma 2022" (Nomination Committee appointed for IRLAB's Annual General Meeting 2022). It details the composition of the Nomination Committee for the upcoming AGM. This type of announcement, concerning the setup or process related to the Annual General Meeting (AGM), falls under the scope of AGM Information (AGM-R). Although it mentions the AGM, it is not the proxy statement (DEF 14A/PSI) or the voting results (DVA), but rather preparatory information about the committee responsible for nominating board members for the meeting.
2021-11-05 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for IRLAB Therapeutics AB covering the period April to June 2021. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow analysis, and management commentary on business performance and clinical trials. It is not a mere announcement of a report, but the report itself, containing substantive financial data. Q2 2021
2021-08-25 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report April – June 2021' and contains comprehensive financial statements, including income statements, balance sheets, and cash flow statements for the group and parent company. It also includes management commentary, project portfolio updates, and key financial ratios. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q2 2021
2021-08-25 English
Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease
Regulatory Filings Classification · 95% confidence The document is a press release dated July 15, 2021, announcing a 'licensing agreement' between Ipsen and IRLAB regarding the development and commercialization of a drug candidate (mesdopetam) for Parkinson's disease. This type of announcement details a significant corporate transaction involving rights, financial terms (upfront payment, milestones, royalties), and future development responsibilities. This clearly falls under corporate financing or strategic activity, but not a standard regulatory filing like 10-K, ER, or IR. It is a specific announcement about a capital/financing/licensing deal. The closest fit among the provided codes is 'Capital/Financing Update' (CAP), as licensing agreements often involve significant financial considerations and structure changes related to asset development. It is not a management change (MANG), director dealing (DIRS), or a general regulatory filing (RNS). Given the focus on securing exclusive rights and the associated financial structure, CAP is the most appropriate classification.
2021-07-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.